Long-Term Safety of Ezetimibe Added to Atorvastatin in Primary Hypercholesterolemia

Phase 3, randomised, double-blind trial in hypercholesterolemia comparing Placebo + Atorvastatin with Ezetimibe + Atorvastatin (2 arms). Primary endpoints: Percentage of Participants Experiencing ≥1 Adverse Event at 12 months and Percentage of Participants Discontinuing from Study Treatment due to an Adverse Event at 12 months. Started Feb 2001; status: completed.